Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Zelmac Co-Promotion Is Possibility, Firm Indicates

Executive Summary

Novartis may consider a co-promotion partner for the irritable bowel syndrome therapy Zelmac (tegaserod) in the U.S., CEO Daniel Vasella indicated during an Aug. 21 conference call with analysts.

You may also be interested in...

Latest Zelmac Trial Focuses On 12 Mg Dose In Women; Drug Is "Approvable"

Novartis' latest trial for the irritable bowel syndrome agent Zelmac focuses on a 12 mg daily dosing regimen in 1,500 females, with results to be submitted to FDA by the end of the year.

Novartis Rx Exec Changes Include U.S. COO Epstein To Oncology Unit Head

Novartis Pharmaceutical U.S. Chief Operating Officer David Epstein will head the Swiss company's new global oncology business unit effective Sept. 1.

Novartis Alters Zometa Study Design Due To Renal Function Concerns

Novartis is eliminating the 8 mg Zometa arm of its ongoing bone metastases studies, following the detection of elevated serum creatinine levels in some patients.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts